When is a technetium-99m sestamibi parathyroid scan indicated and what is the proper preparation and imaging protocol?

Technetium-99m Sestamibi Parathyroid Scan: Indications, Preparation, and Protocol

Primary Indication

Sestamibi parathyroid scanning is indicated exclusively for preoperative localization of abnormal parathyroid glands in patients with biochemically confirmed primary hyperparathyroidism who are surgical candidates—it has no role in diagnosing hyperparathyroidism. 1, 2, 3

Critical Pre-Imaging Requirements

• Biochemical confirmation must precede imaging: Measure serum calcium (corrected for albumin) and intact PTH simultaneously; hypercalcemia with normal or elevated PTH establishes the diagnosis of primary hyperparathyroidism. 1
• Imaging without biochemical confirmation is inappropriate: The sensitivity of sestamibi is reduced when hypercalcemia is mild or absent, and the test offers no diagnostic value without biochemical evidence of primary hyperparathyroidism. 1
• Surgery must be planned: Preoperative localization should only be performed when parathyroidectomy is being considered, as imaging is performed solely to facilitate minimally invasive parathyroidectomy (MIP), not for diagnosis. 1, 2

Optimal Imaging Protocol

The preferred technique is dual-phase sestamibi with SPECT/CT, which achieves a pooled sensitivity of 86% and positive predictive value of 91-96% for preoperative localization. 4, 1

Technical Protocol Details

• Dual-phase acquisition: Early imaging at 10 minutes and delayed imaging at 120 minutes post-injection captures differential washout between thyroid and parathyroid tissue. 4, 5
• SPECT/CT is essential: The addition of SPECT/CT to planar imaging improves sensitivity from 70% (planar alone) to 86% (with SPECT/CT), providing superior anatomic localization and contrast resolution. 4
• Timing variations: SPECT or SPECT/CT can be acquired at early, delayed, or both time points, though the improved contrast resolution consistently provides more precise anatomic localization. 4

Enhanced Dual-Tracer Protocol

• Adding pertechnetate subtraction increases accuracy: When planar pertechnetate subtraction is combined with dual-phase sestamibi SPECT/CT, sensitivity rises to 93% and positive predictive value to 96%, outperforming dual-phase sestamibi SPECT/CT alone (sensitivity 88%, PPV 92%). 2
• Particular benefit in thyroid disease: In patients with concomitant thyroid nodules, incorporating CT into the dual-tracer (sestamibi + pertechnetate) SPECT protocol increases sensitivity from 80% to 94%. 2, 6
• Interpretation confidence: Adding pertechnetate imaging changes scan interpretation in 14.6% of cases and eliminates the need for additional testing (such as ultrasound) in 12% of patients. 7

Alternative Dual-Tracer Option

• I-123 subtraction technique: The combination of sestamibi and I-123 sodium iodide achieves sensitivities of 75-94% and PPV of 92%, with the advantage of simultaneous dual-energy window acquisition. 4, 8
• European preference: The 2009 European Association of Nuclear Medicine guidelines expressed preference for the dual-tracer sestamibi and I-123 technique, citing improved sensitivity for multigland disease and better distinction of sestamibi-avid thyroid nodules from parathyroid lesions. 4

Patient Preparation

No specific patient preparation is required for sestamibi parathyroid scanning. 9

• No fasting required: Unlike some nuclear medicine studies, patients do not need to fast before sestamibi injection.
• No medication restrictions: Standard medications can be continued.
• Pregnancy and lactation considerations: While not contraindicated, lactating women should consider restricting close contact with breast-fed infants to a maximum of 5 hours in the 24-hour period after administration to minimize radiation exposure. 9

First-Line Imaging Strategy

The American College of Radiology recommends combining ultrasound with sestamibi SPECT/CT as the first-line imaging approach for preoperative localization. 2, 3

Complementary Role of Ultrasound

• Ultrasound sensitivity: Neck ultrasound alone detects abnormal parathyroid glands with sensitivity of 76-80% and positive predictive value of 93-95%, but is highly operator-dependent (range 44-97%). 2
• Ultrasound limitations: Common reasons for failure include ectopic gland location, posterior positioning, multigland disease, small adenoma size, and coexisting thyroid pathology. 2
• Synergistic benefit: Using multiple complementary imaging modalities improves overall sensitivity and positive predictive value, with concordant results from two or more studies reaching sensitivity of 79% and PPV of 86%. 2, 3

Factors That Decrease Sestamibi Sensitivity

Clinicians must recognize clinical scenarios where sestamibi performance is substantially reduced:

• Multigland disease: Sensitivity decreases from 61% in single adenomas to 24-66% in multigland hyperplasia. 4
• Concomitant nodular thyroid disease: Sestamibi-avid thyroid nodules can mask or mimic parathyroid lesions, reducing sensitivity. 4, 6
• Small adenomas: Lesions less than 250-500 mg have reduced detectability. 4, 5
• Mild hypercalcemia: Lower serum calcium levels correlate with decreased sensitivity. 4
• Retained radionuclide: Uptake masked by retained activity in adjacent thyroid or submandibular gland tissue reduces sensitivity. 4

Reoperative Setting

In patients with persistent or recurrent hyperparathyroidism after prior surgery, sestamibi SPECT/CT sensitivity drops to 33-74%, making multimodal imaging essential. 4

Reoperative Imaging Protocol

• Sestamibi with SPECT/CT remains useful: Reported sensitivities of 74% with SPECT/CT and 86% when combined with I-123 in the reoperative setting. 4
• Ultrasound as first-line: A 2017 joint consensus statement of the American Head and Neck Society and the British Association of Endocrine and Thyroid Surgeons recommends ultrasound as first-line imaging in the reoperative setting, citing the advantage of revealing nodular thyroid disease, lymphadenopathy, and postoperative changes. 4
• Consider 4D-CT or MRI: When sestamibi and ultrasound are negative, discordant, or equivocal, 4D-CT (sensitivity 50-91%) or MRI with dynamic sequences (sensitivity 82-93%) should be considered. 4
• Selective venous sampling: Reserved for reoperative candidates when noninvasive examinations yield nonlocalizing, equivocal, or discordant results. 4, 2

Common Pitfalls to Avoid

• Ordering imaging without biochemical confirmation: Sestamibi has no diagnostic value for hyperparathyroidism; diagnosis is biochemical (elevated calcium and PTH). 1, 2, 3
• Relying on planar imaging alone: Planar sestamibi without SPECT/CT has sensitivity of only 70% versus 86% with SPECT/CT. 4
• Ignoring early-phase images: Reviewing early-phase scans can increase localization in 67% of patients with negative delayed scans, with 96% correctly identifying the side of the adenoma. 10
• Assuming negative imaging excludes disease: In multigland disease or small adenomas, sensitivity can be as low as 24-33%; negative imaging does not exclude hyperparathyroidism. 4
• Using sestamibi in pediatric familial hyperparathyroidism: Sestamibi is useful only in older children with single adenomas in sporadic primary hyperparathyroidism, with minimal utility in neonates or familial disease. 4

Clinical Decision Algorithm

1. Confirm biochemical primary hyperparathyroidism (elevated calcium + elevated/inappropriately normal PTH) 1
2. Determine surgical candidacy (imaging only if surgery planned) 1, 2
3. Order dual-phase sestamibi with SPECT/CT plus ultrasound as first-line localization 2, 3
4. Consider adding pertechnetate subtraction if thyroid nodules present or for increased confidence 2, 7
5. If negative/equivocal, proceed to 4D-CT (sensitivity 79-92% for single adenomas) 2
6. In reoperative cases, start with ultrasound, then sestamibi SPECT/CT, then 4D-CT or MRI 4
7. Reserve selective venous sampling for reoperative cases with nonlocalizing noninvasive imaging 4, 2